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Introduction: Danon disease is an extremely rare X-linked dominant disorder characterized by 
progressive cardiomyopathy, muscle weakness, and mild mental retardation. Most cases harbor 
nonsense, frameshift, or splice-site mutations in LAMP2 that result in lysosome-associated 
membrane protein-2 (LAMP-2) deficiency and lysosomal defects. The identification of LAMP2 
mutations makes it possible to detect female carriers with significant cardiomyopathy. Therefore, 
it is of paramount importance to develop useful carrier detection methods. 
Methods: To screen for diminished LAMP-2 expression among female patients with progressive 
cardiomyopathy, we developed a flow cytometric method to detect LAMP-2-deficient 
leukocytes.  
Results: In healthy controls, all circulating leukocyte populations, including granulocytes, 
monocytes, and lymphocytes, expressed significant levels of LAMP-2. In contrast, cells from a 
male patient with Danon disease lacked detectable LAMP-2. His younger twin sisters showed 
reduced levels of LAMP-2 expression with characteristic bimodal fluorescence intensity patterns. 
The percentage of LAMP-2-negative cells in the asymptomatic sibling was nearly the same as 
that in the symptomatic sibling.  
Conclusion: We developed a flow cytometric assay for LAMP-2 expression that can serve as a 
rapid primary screening method to detect carriers of LAMP-2 deficiencies. This assay will 








Danon disease, an X-linked cardioskeletal myopathy, was originally reported as “lysosomal 
glycogen storage disease with normal acid maltase” by Danon et al. in 1981 [1]. The first two 
cases were unrelated young boys, and muscle biopsy led to the diagnosis of characteristic 
vacuolar myopathy in each case. In 2000, Nishino et al. reported that mutations in LAMP2, which 
resides on chromosome Xq24 and encodes the lysosome-associated membrane protein-2 
(LAMP-2), are responsible for the primary defect in Danon disease [2]. LAMP-2, first identified 
in 1983, is a lysosomal membrane glycoprotein. It is critical for the process of autophagy, which 
involves lysosomal fusion to the autophagosome, maturation of autophagic vacuoles, and 
chaperon-mediated protein transport to lysosomes. Autophagy is a cytoprotective pathway that 
eukaryotic cells use to degrade and recycle cytoplasmic contents and prevent starvation [3]. 
Under normal conditions, autophagy represents an important homeostatic mechanism for the 
maintenance of normal cardiovascular function and morphology [4]. Impaired autophagy leads to 
cardiac hypertrophy in LAMP-2-deficient mice [5]. 
Danon disease, which is clinically characterized by the triad of cardiomyopathy, skeletal 
myopathy, and mental retardation, exhibits a large spectrum of clinical characteristics. Dilated 
cardiomyopathy can coexist with hypertrophic cardiomyopathy within a family whose members 
have Danon disease. The clinical presentation of Danon disease is always more severe in males 
than in females because of its X-linked dominance [6]. In male patients, the clinical course is 
progressive and may lead to premature death from arrhythmia or severe heart failure by the end 
of the second or third decade of life. In affected females, the disorder sets in later than it does in 
males and predominantly involves the cardiac muscle. However, the cardiac phenotype can be 
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severe even in some females [7,8]. Even among female patients, heart transplantation is the only 
effective treatment for advanced heart failure [9,10]. 
A case of a symptomatic young female patient was recently reported [11]. Her family members 
were all healthy and did not show any laboratory abnormalities. The patient herself had a de novo 
mutation in LAMP2. Other family cases indicative of germline mutations have been reported [12]. 
Therefore, the absence of familial history should not exclude a diagnosis of Danon disease. Two 
studies strongly suggest that Danon disease occurs more frequently than has been reported. Arad 
et al. detected LAMP2 mutations in 2 of 35 patients with hypertrophic cardiomyopathy [13]. 
Yang et al. identified LAMP2 nonsense mutations in 2 of 50 pediatric hypertrophic 
cardiomyopathy cases [14]. Therefore, a diagnosis of Danon disease should be considered 
whenever a patient with unexplained ventricular hypertrophy is encountered. 
The ability to diagnose Danon disease during its earliest stages is key to determine the most 
appropriate therapeutic intervention, preventing sudden cardiac death, and improving patient 
prognosis. Broad diagnostic screening using a simple and easy method is necessary to diagnose 
more patients. Assaying LAMP-2 expression in the peripheral leukocytes of patients with Danon 
disease is minimally invasive and beneficial [15-17], but this method has not yet been adapted as 
a screening test for asymptomatic patients. 
In the present study, we describe a family with Danon disease that has no apparent inheritance. 
We employed immunohistochemical and flow cytometric analysis to detect LAMP-2 expression 
in the peripheral leukocytes of all family members and identified two preclinical heterozygous 
females (preclinical female carriers). To the best of our knowledge, this is the first report of 
fluorescence-activated cell sorting (FACS) detection of LAMP-2-negative leukocytes being used 
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to screen for Danon disease in females. FACS analysis of leukocytes can contribute to the early 
diagnosis of Danon disease not only in homozygous males but also in heterozygous females.  
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Materials and methods 
 
Study subjects  
A 13-year-old Japanese boy (proband DD1) was referred to our hospital in September 2008 with  
chronic jaundice and elevated liver enzyme levels. Three years earlier, elevated levels of 
transaminases [serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT)] and 
creatine kinase (CK) had been incidentally detected during routine examinations. The enzyme 
levels did not return to normal; in fact, they had increased by July 2008. Physical examination 
revealed muscle weakness in the upper extremities and mild mental retardation. A systolic 
ejection murmur was heard at the second left interspace; therefore, we performed cardiac 
investigations. His chest X-ray revealed mild cardiomegaly (Fig. 1A), whereas ultrasound 
cardiography (UCG) revealed marked hypertrophy in his ventricular septum and left ventricular 
wall without outflow obstruction. The end-diastolic left ventricular dimension was 29.1 mm. 
Systolic and diastolic functions were almost normal. Magnetic resonance imaging (MRI) also 
revealed cardiac hypertrophy with late gadolinium enhancement (Fig. 1B). Electrocardiography 
(ECG) demonstrated distinct giant negative T waves in leads V3-6 and prominent voltages (Fig. 
1C and D). Danon disease was suspected because of the following characteristic symptoms: 
unexplained left ventricular hypertrophy with a giant negative T wave, elevated CK and 
transaminase levels, and muscle weakness in the upper extremities (Table 1). 
The family pedigree of DD1 is shown in Figure 2. No parental consanguinity was present. To the 
best of our knowledge, no other family members showed symptoms of Danon disease at the time 
of initial DD1 presentation. To determine penetrance, we evaluated the parents, sisters, and the 
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maternal uncle of DD1. We also investigated 8 healthy individuals (4 males and 4 females) with 
no signs of specific cardiac or systemic disorders, as controls. 
The Human Research Committee of Kanazawa University Graduate School of Medical Science 
approved this study (No.119), and informed consent was obtained from subjects according to the 
Declaration of Helsinki. 
 
Cardiac function and laboratory data 
All patients and controls underwent physical examinations, chest radiography, ECG, and UCG. 
Left ventricular size and function were evaluated by M-mode and 2-dimensional Doppler and 
color Doppler imaging. Some patients were subjected to MRI studies. Serum levels of 




Genomic DNA was extracted from whole blood using the QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany). Primers were designed to amplify all coding exons of LAMP2, including 
adjacent exon–intron boundaries [2]. Polymerase chain reaction (PCR) fragments were purified 
using the QIAquick PCR purification kit (Qiagen). Sequences were determined in the forward 
and reverse directions using BigDye® Terminator v3.1 and v1.1 cycle sequencing kits (Applied 
Biosystems, Foster City, CA, USA). 
 
Immunohistological detection of LAMP-2  
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Peripheral blood mononuclear cells (PBMCs) were isolated from patients and normal controls by 
Ficoll–Hypaque gradient centrifugation. Slides with PBMC cytospin preparations were air dried 
and fixed in cold acetone. LAMP-2 expression was examined by immunohistochemistry using an 
anti-LAMP-2 antibody (BD Biosciences Pharmingen™, Tokyo, Japan).  
 
Flow cytometric analysis of leukocytes 
Whole blood was used to simplify the screening method. After incubation with lysis buffer, 
intracellular staining with monoclonal antibodies was performed according to standard 
procedures. In brief, 1 × 10
6
 leukocytes were incubated with 100 ml of Fix solution (BD 
Cytofix/Cytoperm
TM
 plus fixation/permeabilization solution; BD Biosciences Pharmingen) for 20 
min at room temperature. After two washes with this solution, the cells were resuspended in 100 
μl of permeabilization solution, and 4 μl of a primary monoclonal antibody directed against 
LAMP-1/ LAMP-2 (BD Biosciences Pharmingen) or isotype-matched monoclonal antibodies 
(BD Biosciences Pharmingen) were added. LAMP-1 and LAMP-2 are homologous lysosomal 
membrane proteins encoded by distinct genes (LAMP1 is located on 13q34) [18]. LAMP-1 was 
used as a control for the integrity of the preparation. After incubation for 20 min, cells were 
washed twice in the permeabilization solution, resuspended in 200 μl of phosphate-buffered 
saline, and analyzed on the FACS Calibur flow cytometer supported by cellquest software 
(Beckton Dickinson, San Diego, CA, USA). 
 
Sensitivity of flow cytometric analysis for detecting LAMP-2 in leukocytes 
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We mixed varying numbers of granulocytes obtained from a healthy male control and DD1 and 
determined the percentage of LAMP-2-negative cells by flow cytometry. Intracellular staining 





Clinical characterization of female carriers 
The sisters of DD1 (DD2 and DD3) were monozygotic twins. One developed mild 
cardiomyopathy, whereas the other did not. No abnormalities were observed in DD2 during her 
school medical check-up (which included ECG) at the age of 6. She was 11 years old when we 
examined her. Although she did not exhibit any obvious symptoms of cardiac disease, mild left 
ventricular hypertrophy was observed by UCG. No late gadolinium enhancement was observed 
on MRI (Fig. 1B). Her ECG demonstrated intermittent Wolff–Parkinson–White syndrome (Fig. 
1C) and grade 2 atrioventricular block. Her AST and LDH levels were slightly elevated (Table 
1), and she did not exhibit skeletal myopathy or mental retardation, thus making her family 
history of Danon disease the only clue to an accurate diagnosis.  
DD3 was screened simultaneously with DD2. She also did not exhibit definitive symptoms. 
Compared with DD2, her chest X-ray, UCG, MRI, and ECG results were normal (Fig. 1). 
Transaminase levels were not elevated and no muscle weakness was detected (Table 1). The 
parents of DD1 exhibited no overt clinical symptoms. No abnormalities were identified in their 
ECG, UCG, or blood enzyme levels. The ECG and UCG findings of DD1’s maternal uncle were 
also normal. 
 
Molecular characterization  
No LAMP2 mutations were detected in DD1’s parents (II-4 and II-3). In contrast, we identified a 
4-bp deletion in LAMP2 at the intron 6 splice site (IVS6+1_4delGTGA) in DD1 (Fig. 3). DD2 
and DD3 were found to be heterozygotes with one copy each of the wild type (upper sequence) 
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and IVS6+1_4delGTGA (lower sequence) sequences. LAMP2 mutations were not detected in any 
of the control samples.  
 
Immunohistochemistry 
Representative LAMP-2 expression profiles in PBMCs are shown in Figure 4. All control 
monocytes (open arrow heads) and a significant portion of the control lymphocytes expressed 
LAMP-2. Some lymphocytes had less cytoplasm, making it difficult to judge the intracellular 
LAMP-2 expression microscopically. Therefore, we analyzed LAMP-2 expression in monocytes. 
DD1’s monocytes lacked detectable LAMP-2 immunoreactivity (arrows). The heterozygote 
females (DD2 and DD3) possessed both LAMP-2-positive (open arrow heads) and 
LAMP-2-negative monocytes (arrows). This chimerism was confirmed by FACS.  
 
FACS analysis of leukocytes  
We first quantified intracellular LAMP-2 expression in each leukocyte subpopulation obtained 
from the peripheral blood samples of normal controls (Fig. 5). LAMP-2 was expressed in all cell 
types, but the signal was more intense in granulocytes, monocytes, and CD56
+







 lymphocytes. Monocytes expressed LAMP-2 as intensely as granulocytes. 
Because large leukocytes could have been included in the monocyte region of the plot, we chose 
to use granulocytes for patient analysis and gated the granulocyte region.  
An investigation of the sensitivity of the FACS data showed that we could detect very small 




Healthy controls showed a single LAMP-1-positive peak and a single LAMP-2-positive peak 
(Fig. 7). Only representative data are shown in Figure 7. Approximately 99.5% to 99.9% (mean 
99.7%) of the cells in healthy control samples were LAMP-2 positive. DD1 showed a single 
LAMP-2-negative peak and a LAMP-1-positive peak, indicating a deficit of LAMP-2 in all of 
DD1’s leukocyte subpopulations. In contrast, the LAMP-1-positive peak displayed the same 
intensity as that in the healthy controls. 
The two heterozygous females (DD2 and DD3) showed identical patterns of double peaks. The 
fluorescence intensities of their LAMP-2-negative peaks were the same as those for DD1, 
indicating a deficit in LAMP-2 expression in these cells. The intensities of their 
LAMP-2-positive peaks, however, were the same as those of the healthy controls, indicating 
normal LAMP-2 expression in these cells. Although DD3 was asymptomatic, the percentage of 
her LAMP-2-negative cells was similar to that in symptomatic DD2. To prove that the LAMP-2 
negative cells contained no lymphocytes, we purified the granulocytes by Ficoll–Hypaque 
gradient centrifugation and analyzed them by the same FACS method. The double peaks 
reappeared, revealing that the granulocytes of the female patients consisted of either 
LAMP-2-positive or LAMP-2-negative cells. In summary, a single LAMP-2-negative peak in 







Since 2000, Danon disease has been diagnosed by PCR-based mutation detection technologies 
and Western blot analysis of LAMP-2 expression. Almost all reported LAMP2 mutations lead to 
LAMP-2 protein loss through frameshift or nonsense mutation. However, in 2010, Yang 
discovered LAMP2 microdeletions in patients with Danon disease [19]. In these cases, LAMP-2 
was undetectable, but short range PCR-based mutation detection technologies missed these 
patients, providing a compelling argument for employing both genetic and protein expression 
analyses to diagnose Danon disease.  
Here we describe the development of a flow cytometric assay that greatly facilitates the detection 
of females heterozygous for Danon disease. The assay is based on the detection of the lysosomal 
protein LAMP-2 in peripheral blood leukocytes. In normal controls, all circulating leukocyte 
populations, including granulocytes, monocytes, and lymphocytes, expressed significant levels of 
LAMP-2. This assay can be used for any patient with or without symptoms of Danon disease; it 
takes less time and is less expensive than genetic analysis. Accordingly, it is more suitable as an 
initial screening process.  
Males have one copy of the X chromosome; thus, all cells from male patients with Danon disease 
lacked detectable LAMP-2. A potential imbalance of gene expression from the two X 
chromosomes in females is resolved by inactivating one X chromosome. X-chromosome 
inactivation is a stochastic event that occurs during the early stages of embryonic development. In 
each cell, a choice is made independently. Therefore, there are two possible patterns of LAMP-2 
expression in female patients with Danon disease: positive expression by normal paternal X 
chromosomes and negative expression by affected maternal X chromosomes. 
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Primary immunodeficiency diseases such as X-linked agammaglobulinemia and Wiskott–Aldrich 
syndrome are diagnosed by protein expression analysis using FACS. In these X-linked inherited 
diseases, heterozygous females usually do not exhibit clinical symptoms, with the exception of 
some rare cases. Protein levels in the tissues of affected females can be reduced because of 
skewed X-chromosome inactivation. Fanin et al. reported an X-chromosome inactivation analysis 
in three female patients of Danon disease and found a random pattern of inactivation in 
leukocytes. The mean skewing rate in blood leukocytes was 60% [17]. 
We believe that our analysis can demonstrate chimerism, even if some female patients with 
Danon disease show small percentages of LAMP-2-negative cells by skewed X-chromosome 
inactivation, because we could detect as few as 0.8% of cells lacking LAMP-2 (Fig. 6). The 
sensitivity of flow cytometric assay, which can detect the fluorescent intensity of each cell, is 
much higher than that of Western blot analysis. On the other hand, LAMP-2 is expressed in all 
leukocytes in healthy males and females; therefore, LAMP-2-negative cells could not be detected 
by flow cytometric assay. This indicates that both the sensitivity and specificity of this assay are 
extremely high. Nevertheless, confirmation by genetic analysis is necessary. 
We used our assay to detect LAMP-2 expression in a family that has a male member who suffers 
from Danon disease. There was no apparent inheritance, although we were able to identify two 
young heterozygous females (DD2 and DD3) without the clinical onset of Danon disease. The 
clinical courses of DD2 and DD3 should prove to be highly informative about the early stages of 
Danon disease. DD2 and DD3 are monozygotic twins with identical leukocyte LAMP-2 
expression and LAMP2 mutations; DD2 was symptomatic, whereas DD3 was asymptomatic. In 
addition, there were no differences in their lifestyles. We were therefore unable to account for the 
differences in their clinical findings. Using our flow cytometric assay, we can investigate 
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LAMP-2 expression not only in leukocytes but also other cells and tissues. Such a study could 
explain the complex organ-specific symptoms and different severity among patients with Danon 
disease. 
Inherited cardiomyopathies are genetically heterogeneous [20]. A majority of childhood-onset 
isolated cardiac hypertrophies are caused by genetic mutations for which adults are routinely 
screened [21,22]. However, in some young patients, nonsarcomeric causes such as inborn errors 
of metabolism, mitochondrial dysfunction, and neuromuscular conditions have been increasingly 
recognized [23], and the outcomes depend largely on the cause [24]. Among all causes of 
ventricular hypertrophy, the clinical course of Danon disease is the most aggressive. Early 
diagnosis of Danon disease should be highly informative of prognosis, and this disease should 
always be ruled out in patients presenting with unexplained cardiomyopathy. 
Our present study demonstrates that flow cytometric analysis of LAMP-2 expression by 
leukocytes provides a novel, rapid, simple, and highly sensitive screening method for the early 
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Table and Figure legends 
 
Table 1 Clinical findings of patients 
 DD1 (III-4) DD2 (III-5) DD3 (III-6) 
Control 
(n=8) 
Sex Male Female Female N/A 
subjective 
symptom 
General fatigue Palpitation None None 
Age at diagnosis 14 years 11 years 11 years 10-14years 
Diastolic 
LVPWD (mm) 
25.8 12.1 6.9 7.0 ± 0.3 
Diastolic IVSD 
(mm) 
21.7 10.8 7.0 6.7 ± 0.4 
ECG abnormality 





block (II)  
None None 
muscle weakness Upper extremities None None None 
Mental 
retardation 
None None None None 
CK (IU/l) 567 156 125 134 ± 47 
AST (IU/l) 185 67 19 24 ± 5 
ALT (IU/l) 150 27 13 12 ± 4 
LDH (IU/l) 924 516 179 199 ±25  





Figure 1 Images of patients. (A) Chest X-ray. Enlargement of a central shadow is observed in 
DD1. (B) A short-axis view of gadolinium-enhanced cardiac magnetic resonance imaging. 
Images of DD1 show marked hypertrophy of the left ventricular wall and late gadolinium 
enhancement below the epithelium. Images of DD2 show milder hypertrophy than DD1 and no 
late gadolinium enhancement. Neither hypertrophy nor late gadolinium enhancement was 
observed on images of DD3. (C) V5-lead from a resting 12-lead electrocardiogram (ECG). ECG 
of DD1 shows prominent voltage and a giant negative T wave, whereas that of DD2 shows a 
short PR interval. DD3 has no ECG abnormalities. (D) Full resting 12-lead ECG of DD1. 
 
 
Figure 2 Pedigree of DD1. III-4 (DD1) is the proband and III-5 (DD2) and III-6 (DD3) are 





Figure 3 Mutation detection in the family. Deletion of GTGA at the 3′ end of exon 6 is 
demonstrated in the genomic DNA of DD1 (hemizygous) and of DD2 and DD3 (heterozygous) 
but not in that of the parents (II-3 and II-4). 
 
 
Figure 4 Immunoreactivity in peripheral blood mononuclear cells. The control shows 
lysosome-associated membrane protein-2 (LAMP-2) expression in all peripheral blood 
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mononuclear cells. DD1 has no detectable LAMP-2 expression, and both DD2 and DD3 show 
chimerism, i.e. LAMP-2-positive and LAMP-2-negative cells. △, LAMP-2-positive monocyte; 
→, LAMP-2-negative monocyte. 
 
 
Figure 5 Intracellular lysosome-associated membrane protein-2 (LAMP-2) expression in 
leukocyte subpopulations. LAMP-2 expression is more intense in granulocytes (Gr), monocytes 
(Mono), and CD56
+
 NK cells (CD56
+











Figure 6 Quantitative analysis of lysosome-associated membrane protein-2 
(LAMP-2)-negative cells. (A) Actual percentages of LAMP-2-negative cells are shown on left 
side of each panel, and measured percentages are shown in each panel. (B) Measured percentages 
of LAMP-2-negative cells are consistent with actual percentages. FITC, fluorescein 





Figure 7 LAMP-1 and LAMP-2 expressions by granulocytes. DD1 has no detectable LAMP-2 
expression but expresses normal LAMP-1 levels. DD2 and DD3 show two peaks of LAMP-2 
expression. The lower peak is of the same intensity as that for DD1. Therefore, this peak can be 
attributed to LAMP-2-negative cells. The higher peak shows the same LAMP-2 signal intensity 
as that shown by healthy controls. These data indicate that granulocytes of female patients 
contain LAMP-2-negative and LAMP-2-positive cells. The ratio of LAMP-2-positive to 
LAMP-2-negative cells exhibited by DD2 is similar to that displayed by DD3.  
 
LAMP, lysosome-associated membrane protein; FITC, fluorescein isothiocyanate. 
 
Hashida 29 
 
 
